Pubmed (TDAH) du 19/03/26
1. Adamis D, Zhang T, Gavin B, McNicholas F. Prevalence and moderators of personality disorders in adults with ADHD: A meta-analysis. Psychiatry Res. 2026; 360: 117085.
This meta-analysis investigated the prevalence and moderators of personality disorders (PDs) in adults with Attention-Deficit/Hyperactivity Disorder (ADHD), synthesizing data from 11 studies encompassing 2120 participants across clinical and nonclinical settings. The results indicate a substantial but highly variable burden of personality pathology, with a pooled prevalence for the presence of at least one comorbid PD estimated at 57 % (95 % CI [42-71]). However, this figure was largely driven by specialized outpatient populations, and statistical heterogeneity was exceptionally high (I² > 90 %), suggesting that prevalence is deeply context-dependent. Among specific diagnoses, the highest co-occurrence rates were observed for Passive-Aggressive (25.3 %), Avoidant (23.1 %), and Borderline (21.9 %) personality disorders. Moderator analyses revealed that these estimates were significantly influenced by diagnostic methodology; structured clinical interviews (such as the SCID-II) and self-report inventories (like the MCMI) consistently yielded higher rates than standard clinical assessments. Furthermore, setting played a critical role, with ADHD-specific clinics showing significantly higher coexistence than prison or student samples. While tests for publication bias were non-significant, they were limited by low statistical power. Ultimately, these findings underscore the high frequency of personality-related impairment in adult ADHD while highlighting the challenges of « diagnostic noise » and phenotypic overlap. The extreme fluctuations in reported rates suggest that clinicians must look beyond categorical labels, acknowledging that the identified prevalence is often a byproduct of the specific instruments and clinical frameworks employed.
Lien vers le texte intégral (Open Access ou abonnement)
2. Ay R, Kilincel S, Kilincel O, Hafif A. Internet Addiction and Emotion Regulation Difficulties in Patients Diagnosed With Attention-Deficit/Hyperactivity Disorder. Psychiatry Investig. 2026; 23(3): 321-31.
OBJECTIVE: This study aims to examine the relationship between internet addiction and emotion regulation difficulties in individuals with attention-deficit/hyperactivity disorder (ADHD). METHODS: Sixty-three patients diagnosed with ADHD according to DSM-5 and 63 healthy controls were included in our study. Sociodemographic data form, Adult ADHD Self-Report Scale (ASRS), Young Internet Addiction Scale (YIAS), Difficulties in Emotion Regulation Scale (DERS), Barratt Impulsivity Scale-11 (BIS), and Beck Depression Inventory (BDI) were applied to both groups. RESULTS: According to the independent samples t-test, the ADHD group had higher scores on YIAS (t=4.754, p<0.001), ASRS (t=11.832, p<0.001), DERS (t=7.167, p<0.001), lack of emotional awareness (t=2.411, p=0.017), clarity (t=5.976, p<0.001), non-acceptance of emotional reactions (t=3.724, p<0.001), impulsivity (t=5.976, p<0.001), goal (t=8.298, p<0.001), strategy (t=5.210, p<0.001), and means were found to be statistically significantly higher than the control group (CG). According to the Pearson correlation analysis, no statistically significant correlation was found between the YIAS scores and other scale scores in the ADHD group. According to Pearson correlation analysis, a statistically significant positive correlation was found between the YIAS scores in the CG and the ASRS (r=0.474, p<0.01) and inattention (r=0.450, p<0.01) scores. According to the regression analysis, lack of emotional awareness, non-acceptance of emotional reactions, and BDI were found to be significant predictors of risky internet use. CONCLUSION: It has been determined that risky internet use increases in adults with ADHD and that some emotion regulation difficulties increase the risk.
Lien vers le texte intégral (Open Access ou abonnement)
3. Chiu J, Nikirk J, Brown A, Woolford M. Symptomatic improvement in fibromyalgia after treatment of comorbid attention deficit hyperactivity disorder: a case report. J Med Case Rep. 2026.
BACKGROUND: Attention deficit hyperactivity disorder is a common disorder that has an association with fibromyalgia. The connection between the two is incompletely understood but may be due to specific neurotransmitter abnormalities. Atomoxetine, a selective norepinephrine reuptake inhibitor mainly used for attention deficit hyperactivity disorder, has shown promise in relieving symptoms of attention deficit and chronic pain. However, its effectiveness in treating both conditions simultaneously has not been thoroughly studied. CASE PRESENTATION: We present the case of a 33-year-old white female patient with attention deficit hyperactivity disorder and generalized pain and fatigue from suspected fibromyalgia syndrome. Investigative labs were unremarkable. Atomoxetine was prescribed as the primary treatment intervention to target attentive symptoms. Interestingly, the patient’s symptoms related to both attention deficit hyperactivity disorder and suspected fibromyalgia significantly improved within the first 2 weeks, with continuous relief over the next 9 months. The patient also reported improved quality of mood, sleep, and tolerance of physical activity. CONCLUSION: This case of a 33-year-old female with attention deficit hyperactivity disorder and chronic pain suspicious for fibromyalgia showed the improvement of pain symptoms with atomoxetine. While a few published cases have demonstrated a similar finding, this case is notable for the dramatic improvement and the response to a nonstimulant medication-atomoxetine. This case highlights the need for further research into the connection between attention deficit hyperactivity disorder and chronic pain, as well as the mechanism behind the effects of atomoxetine on pain.
Lien vers le texte intégral (Open Access ou abonnement)
4. Narzisi A, Barbetti F, Fabbri-Destro M, Berloffa S, Fantozzi P, Viglione V, Muccio R, Valente E, Accorinti I, Foti E, Milone A, Cardillo R, Masi G. Cognitive and emotional profiles in children with ASD, ADHD, and comorbid presentations: evidence for a distinct clinical phenotype. Front Psychiatry. 2026; 17: 1765698.
BACKGROUND: Autism Spectrum Disorder (ASD) and Attention-Deficit/Hyperactivity Disorder (ADHD) frequently co-occur, yet their comorbid presentation (ASD+ADHD) remains under- characterized. Clarifying cognitive and behavioral profiles is crucial for accurate diagnosis and effective intervention. METHODS: A total of 207 children and adolescents (ages 6-16) were assessed using the Wechsler Intelligence Scale for Children – Fourth Edition (WISC-IV) and the Child Behavior Checklist (CBCL 6-18). Participants were grouped into ASD (n = 21), ADHD (n = 103), and ASD+ADHD (n = 83) cohorts. Group differences were analyzed through ANOVAs with Bonferroni corrections; Pearson correlations explored associations between cognitive indices and behavioral outcomes. RESULTS: Children with ASD+ADHD scored significantly lower than the ASD group in working memory, processing speed, and full-scale IQ, while no significant differences emerged between the ASD+ADHD and ADHD groups. Behaviorally, ADHD participants exhibited higher externalizing symptoms (e.g., aggression, rule-breaking), while the ASD group showed greater withdrawn/depressed traits. The comorbid group presented the broadest dysregulation, with elevated scores across both internalizing and externalizing domains, including Sluggish Cognitive Tempo and obsessive-compulsive symptoms. Notably, protective associations between cognitive abilities and behavioral regulation, present in ASD and ADHD, were absent in the ASD+ADHD group. CONCLUSIONS: Findings suggest that ASD+ADHD comorbidity represents a distinct clinical profile, marked by compounded cognitive impairments and pervasive emotional-behavioral dysregulation. These patterns underscore the need for differential diagnostic approaches and tailored interventions that account for the unique neurocognitive architecture of comorbid presentations.
Lien vers le texte intégral (Open Access ou abonnement)
5. Pliszka SR. Letter: Polypharmacy and Diabetes in Attention-Deficit/Hyperactivity Disorder: A Comment on Zhu et al. J Child Adolesc Psychopharmacol. 2026: 10445463261434898.
